Taiwan biotechnology, pharmaceutical, medical devices
Returning on 18- 20 March 2019 after a successful 2018 debut, Phar-East will once again bring together experts from Asian pharma & biotechs, big pharma, regulators, payers, technology innovators and more to share their expertise and chart Asia’s path forward.
Read more
In the lead up to the Bio Connections Australia 13-14 November, Melbourne conference, we spoke with US-based pharmaceutical firm, Cerebral Therapeutics, who have recently undertaken a proof of concept clinical study in Australia, using a proprietary formulation to treat refractory epilepsy.
Read more
Organised by IBC Asia, the annual Biopharma Development & Production (BDP) Week took place on 16 – 17 May 2018 at Hilton Shanghai Hongqiao Hotel.
Read moreTaipei, Taiwan-based Lumosa Therapeutics Co., Ltd., a company focused on developing treatments for neurological and inflammatory disease, announced recently that it had engaged Cincinnati-headquartered Camargo Pharmaceutical Services for regulatory consulting and strategic development services for LT1001 (Naldebain®, dinalbuphine sebacate IM injection) in the US.
Read moreSingapore-headquartered ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted treatments for Asia prevalent cancer types, recently announced the signing of a research collaboration agreement with Academia Sinica’s Genomic Research Centre, one of Taiwan’s leading research institutions.
Read moreIn Taiwan, biotech is finally booming, and new companies, service providers and manufacturing facilities are emerging to fill rapidly growing industry needs. BioSpectrum Asia recently spoke to Dr. Apo Huang, Secretary General, BioTaiwan on the current growth in the Taiwanese biotech sector.
Read more
